Oct 14, 2023 · The preclinical results provide evidence that ITRI AXN eye drops could effectively deliver therapeutics to the choroid and retina for antiangiogenic therapy.

The unique eye drop formulation, termed ITRI AXN eye drops, was obtained from self-assembly of (2-hydroxypropyl)-β-cyclodextrin with a VEGF tyrosine kinase inhibitor, a hydrophilic polymer, hypromellose, and a complex stabilizer, caffeine.

Topical administration of ITRI AXN eye drops was designed to serve as an alternative treatment of nADM, to replace the current invasive intravitreal injection of an anti-VEGF antibody.

A VEGF tyrosine kinase inhibitor, a hydrophilic polymer called hypromellose, and a complex stabilizer called caffeine was used to self-assemble the novel eye drop formulation, known as ITRI AXN eye drops.

ITRI’s AXN eye drops has demonstrated high drug exposure in posterior eye tissue and good efficacy in several animal models. No ocular irritation observed. IND filing is planed in 2022 Q2. The drug exposure at retina can remain higher than 100-fold IC50 of drug in 24 h for the rabbits receiving ITRI eye drop with a dosing frequency of TID.

ITRI's coordinated supramolecular composite carrier technology utilizes molecular-level carriers with high surface-hydrophilicity to encapsulate drugs, which can effectively promote drug solubility and drug tissue penetration, especially in ocular tissues.

Dec 21, 2021 · Translational relevance: The preclinical results provide evidence that ITRI AXN eye drops could effectively deliver therapeutics to the choroid and retina for antiangiogenic therapy.

Dec 1, 2021 · The preclinical results provide evidence that ITRI AXN eye drops could effectively deliver therapeutics to the choroid and retina for antiangiogenic therapy, and the eye drop formulation has demonstrated great promise in antiangIogenic therapy against retinal and choroidal neovascularization in animal models.

Methods: The unique eye drop formulation, termed ITRI AXN eye drops, was obtained from self-assembly of (2-hydroxypropyl)-β-cyclodextrin with a VEGF tyrosine kinase inhibitor, a hydrophilic polymer, hypromellose, and a complex stabilizer, caffeine.

Dec 1, 2019 · The preclinical results provide evidence that ITRI AXN eye drops could effectively deliver therapeutics to the choroid and retina for antiangiogenic therapy, and the eye drop formulation has demonstrated great promise in antiangIogenic therapy against retinal and choroidal neovascularization in animal models.